QI
CTMX icon

QS Investors’s CytomX Therapeutics CTMX Stock Holding History

QS Investors’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$322K Buy
+50,800
New +$396K ﹤0.01% 917
2018
Q3 		– Sell
-370
Closed -$8K – 1917
2018
Q2 		$8K Hold
370
– – ﹤0.01% 1579
2018
Q1 		$11K Hold
370
– – ﹤0.01% 1556
2017
Q4 		$8K Hold
370
– – ﹤0.01% 1571
2017
Q3 		$7K Buy
+370
New +$5.77K ﹤0.01% 1613

Other funds holding CTMX

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

QS Investors's CTMX Position: Q2 2021 in Review

QS Investors opened a new position in CytomX Therapeutics (CTMX) in Q2 2021: 50,800 shares worth $322K. The stake represents ﹤0.01% of the portfolio and ranks #917 among its holdings. This is a return to the name: QS Investors previously reported a position in CTMX as recently as Q2 2018.

QS Investors first reported a position in CTMX in Q3 2017 and has held it in 5 quarters since. 122 funds tracked by Wall St. Rank hold CTMX as of Q2 2021.

  • QS Investors held 50,800 shares of CytomX Therapeutics worth $322K as of Q2 2021.
  • CytomX Therapeutics was a new QS Investors position in Q2 2021.
  • CytomX Therapeutics made up ﹤0.01% of QS Investors's portfolio in Q2 2021, its #917 holding.
  • QS Investors first reported a position in CytomX Therapeutics in Q3 2017 and has held it in 5 quarters since.
  • 122 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.